
July 16 (Reuters) - Johnson & Johnson JNJ.N:
J&J: ANTICIPATE SECOND HALF OPERATIONAL SALES GROWTH HIGHER THAN FIRST HALF - PRESENTATION
J&J: IN INNOVATIVE MEDICINE, NEGATIVE IMPACT OF PART D RE-DESIGN, AS A PERCENT TO SALES, WILL BE CONSISTENTLY APPLIED THROUGHOUT YEAR
J&J: PRODUCTS NEGATIVELY IMPACTED BY PART D RE-DESIGN INCLUDE STELARA, INVEGA LONG ACTING INJECTABLES, ERLEADA, OPSUMIT, UPTRAVI, TREMFYA & IMBRUVICA
Source text: [ID:]